D816V KIT mutation of bone marrow (BM) mast cells (MC) is a common feature to systemic mastocytosis (SM) patients. Nevertheless, occurrence of the KIT mutation in BM cell compartments other than MC is associated with progression to more aggressive forms of the disease and poor outcome in indolent SM (ISM). Here, we assessed the potential association between the immunophenotype of MC and multilineage KIT mutation in the BM of SM patients through the investigation of the flow cytometric protein expression profile (PEP) of bone marrow mast cells (BMMC) from 70 control individuals and 206 SM patients, classified according to the WHO (World Health Organization), and the degree of involvement of BM hematopoiesis by the D816V KIT mutation; additionally, we developed a score-based class prediction algorithm for the detection of SM cases with multilineage mutation. Our results show that aberrant expression of CD25 with a FceRI lo , FSC lo , SSC lo and CD45 lo immature phenotype of BMMC, in the absence of coexisting normal MC in the BM, was associated with multilineage involvement by the D816V KIT mutation, regardless of the diagnostic subtype of the disease (for example, indolent vs aggressive SM), which supports the utility of the immunophenotype of BMMC as a surrogate marker to screen for multilineage KIT mutation in ISM.
INTRODUCTION
Mastocytosis is a heterogeneous group of disorders characterized by an abnormal growth and accumulation of neoplastic mast cells (MC) in one or more organ systems. 1, 2 It includes patients with both mild---for example, cutaneous mastocytosis and indolent systemic mastocytosis (ISM)---and more aggressive---for example, aggressive SM (ASM) and MC leukemia (MCL)--forms of the disease, together with cases that have an associated clonal non-MC lineage disease (SM-AHNMD). 1, 2 Recently, two additionally rare but clinically and molecularly distinct subvariants of ISM have been identified, which have relevant therapeutic implications: (i) ISM without skin lesions (ISM sÀ ) 3--5 and (ii)well-differentiated SM. 6--8 Despite the clinical, biological and prognostic heterogeneity found among the different subtypes of SM, in the great majority (490%) of cases, the clonal nature of MC is demonstrated by the presence of the stem cell growth factor receptor gene (KIT) D816V mutation, 9 except among well-differentiated SM patients; thus, the presence of KIT mutation itself, is of relatively limited value for the classification of the disease. 1, 9 Interestingly, recent studies 9 showed that poor-prognosis SM, including ASM, MCL and SM-AHNMD 2,10 frequently (E80% of the cases) carry the D816V KIT mutation in myeloid or both myeloid and lymphoid hematopoietic cell compartments other than bone marrow mast cells (BMMC). 9 Noteworthy, BMMC from these later subgroups of SM patients exhibit a unique and more immature immunophenotypic profile---for example, increased expression of HLA-DR and CD123, and decreased reactivity for CD117, FceRI and cytoplasmic (Cy) tryptase 11--14 ---vs other subtypes of SM in which the KIT mutation is typically restricted to BMMC (for example, ISM sÀ ) with a mature activated MC phenotype, and increased expression of multiple activation associated-markers (for example, CD63, CD69 and CD203c). 14 As in ISM sÀ , the majority of ISM patients who have skin lesions (ISM s þ ) typically carry the KIT mutation restricted to the MC compartment; nevertheless, in around 20% of these cases 9 the KIT mutation is also detected in other myeloid or both myeloid and lymphoid cell compartments. Noteworthy, the extent of involvement of hematopoiesis by the KIT mutation has been recently reported to be the most powerful independent prognostic criteria for progression of ISM to more aggressive disease---for example, ASM, myelodysplastic syndrome or acute myeloblastic leukemia. 15 However, this information requires complex molecular analyses of highly purified FACS (fluorescence-activated cell sorting)-sorted BM cell populations, 9, 15 which limits its routine use out of highly specialized reference centers. Despite all the above, no study has been reported so far, in which the potential association between the immunophenotype of BMMC and multilineage involvement by the KIT mutation has been investigated, in order to determine the potential utility of the flow cytometric assessment of the immunophenotypic profile of BMMC in the diagnostic screening of multilineage involvement of hematopoiesis by the KIT mutation in SM.
In this study, we analyzed the flow cytometric PEP of BMMC from 206 SM patients, and compared it among individuals classified according to the WHO disease subtype, as well as the grade of involvement of BM hematopoiesis by the KIT D816V mutation. Our results show that SM patients who carry the KIT D816V mutation in BM cell compartments, other than MC, share a unique PEP on their BMMC, independently of the diagnostic subtype of the disease. These results suggest that immunophenotype of BMMC may be used as a surrogate marker for the diagnostic screening of multilineage KIT mutation in ISM.
MATERIALS AND METHODS Patients
Only adult patients (418 years), who gave their informed consent and fulfilled the WHO, and more recent criteria 1,2 for the diagnosis of ISM sÀ , ISM s þ or ASM (including those cases with AHNMD) were included in the study; additionally, those patients who carried a KIT mutation distinct from the D816V or in whom the KIT mutation could not be investigated in all the subpopulations of nucleated BM cells, were excluded from further analyses. Overall, 206 BM samples obtained from an identical number of SM patients (141 ISM s þ , 18 ASM and 47 ISM sÀ ) who fulfilled the inclusion criteria (111 males and 95 females; median age of 44 years, ranging from 21 to 77 years), and who were diagnosed at the reference centres of the Spanish Network of Mastocytosis (REMA) (Mast Cell Unit of the Hospital Virgen del Valle, Toledo, and Cytometry Service of the Cancer Research Centre, Salamanca, Spain) were studied. In addition, 70 control BM donors (27 males and 43 females; median age of 47 years, ranging from 25 to 77 years), which consisted of 5 healthy subjects and 65 patients undergoing BM aspiration for clinical reasons other than mastocytosis, were also analysed. Of note, a subset of 55 patients and 20 control BM donors included in this study were also previously described in reference Teodosio et al.
14 In all cases, informed consent was obtained prior to the study, according to the guidelines of the local ethics committees and review boards of the two centres.
Multiparameter flow cytometry immunophenotype of BMMC Multiparameter flow cytometry immunophenotypic studies were performed on BM aspirate samples, processed as previously described, 14, 16 using either a FACSCalibur (Becton Dickinson--BD, San Jose, CA, USA) or a FACSCanto II flow cytometer (BDB), equipped with the CellQUEST and FACSDiva software programs (BDB), respectively. Four-color, fluorescein isothiocyanate (FITC)/phycoerythrin (PE)/peridinin chlorophyll protein (PerCP)--cyanin 5.5 (Cy5.5)/allophycocyanin, combinations of monoclonal antibodies (MAb) were used to stain BM cells for a broad set of proteins ( Table 1 ). For those BM samples measured in the FACSCanto II flow cytometer (n ¼ 51), a six-color, Pacific Blue/Pacific Orange /FITC/PE/PerCP Cy5.5/PE--cyanin 7 (Cy7), combination of MAb was used (Table 1 ). In both groups of cases, a double-step acquisition procedure was applied, as recommended by the REMA. 17 For data analysis the INFINICYT software (Cytognos SL, Salamanca, Spain) was used.
Serum tryptase levels
Serum tryptase (sT) levels were determined using the Phadia ImmunoCAP Tryptase System (Phadia, Uppsala, Sweden), according to the instructions of the manufacturer.
Purification of MC and other subpopulations of BM nucleated cells, and detection of KIT D816V mutation Isolation of MC and other subpopulations of nucleated BM cells was performed using a four-way fluorescence-activated cell sorter (FACSAria, BDB), equipped with the FACSDiva software (BDB) as described elsewhere. 9 The KIT D816V mutation was detected using a peptide nucleic acidmediated PCR-clamping technique, on highly-purified fractions (X97% purity) of BMMC, eosinophils, monocytes, neutrophils, CD34 þ hematopoietic precursor cells and lymphocytes, as previously described; 9 in these later fractions no contamination by phenotypically aberrant MC was detected (o0.01%).
Statistical methods, hierarchical clustering analysis and class prediction algorithm
For all continuous variables, their median, mean and s.d., as well as range and both the 25th and 75th, and the 10th and 90th percentiles were calculated; for categorical variables, frequencies were reported. Statistical significance (P value p0.05) was determined employing the nonparametric Kruskal--Wallis and Mann--Whitney U tests (for continuous variables) or the Pearson's Chi-square test, the binomial test and Fisher's exact test (for categorical variables). Progression-free survival (PFS) curves were plotted according to the method of Kaplan--Meier and survival curves were compared using the log-rank test. For all statistical analyses the SPSS 15.0 software (SPSS, Chicago, IL, USA), was used.
Unsupervised hierarchical clustering analysis was performed using standard correlation coefficients (Pearson correlation) and the average linkage clustering method. Normalization of the datasets was performed by calculating a ratio between the mean fluorescence intensity obtained for each marker and the median mean fluorescence intensity value obtained for that marker in all the samples tested. A logarithmic (base 2) transformation was applied to the ratio values, and the log2 ratios were then used for hierarchical clustering analyses (Cluster 3.0 and Tree View software; Stanford University, Stanford, CA, USA).
In order to explore the predictive value of the different immunophenotypic features for the detection of cases with multilineage KIT mutation, a score-based class prediction model was built, employing a training set of ISM s þ patients. For the identification of the most discriminant parameters and categorization of continuous variables, receiver operating characteristic (ROC) curves were applied. Those variables that did not reach statistical significance (P40.05), had little discriminating value (area under the curve (AUC)o0.6), and/or were tested in o80% of the samples analyzed, were excluded from the model. Normalization of each immunophenotypic variable was performed by calculating the ratio between individual mean fluorescence intensity values of SM patients and the median mean fluorescence intensity value obtained for a reference group of normal BMMC, stained and measured under identical conditions as that of the SM patients' samples. The performance of individual markers for the classification of SM patients with multilineage KIT D816V mutation vs patients with KIT mutation restricted to BMMC was determined using ROC curves. Accordingly, a score of two was assigned to those variables with higher discriminating power (AUC40.7), whereas for the remaining informative variables a score of one was attributed. The result of the sum of the score for the five parameters included in the model was assigned as the score of each individual sample; then the most discriminant score cutoff for KIT multilineage involvement was determined using a ROC curve. This classifier was then used to predict the class in a validation set of samples stained with the same combination of MAbs, but measured in a different four-color flow cytometer (validation set no. 1, that corresponds to the subset of 55 patients and 20 control BM donors, which were previously described in Teodosio et al.
)
, and a second validation set of patient samples stained with six-color combinations of MAbs and measured in a FACSCanto instrument (validation set no. 2). Sensitivity was calculated as true positive (TP)/(TP þ false negative), specificity as true negative (TN)/(TN þ false positive), positive predictive value as TP/(TP þ false positive), negative predictive value as TN/(TN þ false negative), false positive rate as 1Àspecificity and false negative rate as 1Àsensitivity.
RESULTS
Unsupervised hierarchical clustering-based classification of SM patients according to the load and immunophenotypic features of BMMC In a first step, unsupervised hierarchical clustering analysis was performed on 112 SM patients, who were simultaneously tested for a screening panel of a limited number of parameters (n ¼ 11) (stained and measured under the same conditions). On the basis of this analysis, patients were classified into two major groups (groups A and B in Figure 1a ): one group (group A) included most ASM cases (11/12 (92%; P ¼ 0.006)), whereas the other (group B) comprised the majority of ISM sÀ patients (25/27 (93%; Po0.0001)). Interestingly, ISM s þ patients were equally distributed in both groups: 49% in group A and 51% in group B (P ¼ 0.91). Nevertheless, when the pattern of BM involvement by the KIT mutation was considered, group A included the majority of SM patients with myeloid, and myeloid plus lymphoid KIT mutation (14/19 (74%; P ¼ 0.04) and 12/15 (80%; P ¼ 0.02), respectively). Conversely, group B included 55/78 (71%; Po0.0001) cases with the KIT mutation restricted to BMMC (Figure 1a) . In order to further confirm these results, a similar analysis with a larger number of phenotypic parameters was performed, for a subset of 34 patients ( Figure 1b) and a separate new set of patients (n ¼ 35), evaluated in a distinct FACSCalibur flow cytometer instrument (Figure 1c) . Both groups displayed clustering profiles, which were similar to those observed for the first group of patients (Figure 1a ).
Flow cytometric protein expression profiles of BMMC from ISM s þ patients with different degree of BM involvement by the D816V KIT mutation In detail, ISM patients with involvement of multiple myeloid and/ or lymphoid BM cell compartments by the KIT mutation displayed increased numbers of phenotypically aberrant CD25 þ BMMC (P ¼ 0.008), and higher sT levels (P ¼ 0.01) (Figure 2) , with values closer to those detected in ASM vs both ISM sÀ and ISM s þ cases with KIT mutation restricted to BMMC. Furthermore, coexistence of normal and aberrant BMMC populations was restricted to SM patients with KIT mutation restricted to the BMMC compartment (17.6% vs 0%; P ¼ 0.0004). In addition, an increasing number of mutated BM cell compartments were associated with significantly (Po0.05) lower light scatter values, reflected also by a decreased content of cytoplasmic MC enzymes, such as carboxypeptidase A and total tryptase (Figure 2 ). In line with this, expression of other maturation-associated markers, such as CD203c, the high-affinity IgE receptor (FceRI) (P ¼ 0.02), CD45 (P ¼ 0.01) and CD9 (P ¼ 0.009), was also significantly lower among cases with mutilineage KIT mutation. Interestingly, ISM s þ cases with both myeloid and lymphoid BM involvement displayed slightly (but not significantly) decreased expression of the CD63 and CD69 activation markers (Figure 2) . Performance of the prediction algorithm for the classification of SM patients On the basis of the above findings, an algorithm, for the classification of SM patients with multilineage KIT D816V mutation vs patients with KIT mutation restricted to BMMC, was built ( Figure 3 ). For the development of the algorithm, an immunophenotypic score was established using those phenotypic markers (% of BMMC, FSC, SSC, CD45 and FceRI), which were tested in 480% of the patients, and had a high individual discrimination power (AUC40.6; Po0.05) between BMMC from ISM s þ cases with KIT mutation restricted to MC and cases with multilineage involvement, and a training set of ISM s þ patients in which all these variables were simultaneously analysed (n ¼ 75) ( Table 2) . Using this algorithm, patients with multilineage KIT mutation were identified based on aberrant expression of CD25 by BMMC, absence of a coexisting normal BMMC population and an immunophenotypic score 43 (Figure 3) . This approach displayed a high efficiency to classify patients according to the degree of involvement of hematopoiesis by the KIT mutation, with high sensitivity (range: 80--92%) and specificity (range: 71--94%) when assessed in both the training and the two validation groups of SM patients; similar results were found when ISM s þ patients, and the overall group of SM patients were considered, which proves the efficiency of the proposed algorithm in SM, independently of its specific diagnostic subtype (Table 3) .
Prognostic impact of the PEP of BMMC on PFS of ISM s þ patients
Once the potential impact of PEP of BMMC from ISM s þ patients on patient outcome was investigated in a subset of 116 ISM s þ patients with a follow-up of X22 months (median of 126 months (range: 22--596 months) after disease onset), we found a significant adverse impact on PFS for an immature BMMC phenotype, as defined by the proposed algorithm (based on the aberrant expression of CD25 and BMMC phenotypic score 43, in absence of a coexisting normal BMMC population) (Figure 4a ). Five patients (4%) who showed signs of progression according to Escribano et al. 15 60, 76, 249, 310 and 428 months after disease onset, also had myeloid (n ¼ 2) or myeloid plus lymphoid (n ¼ 3) BM involvement by the KIT D816V mutation; thus, the phenotypic score showed a very similar impact on PFS to that of the presence of multilineage KIT D816V mutation (P ¼ 0.001 in both cases).
DISCUSSION
SM includes a group of clinical, biological and prognostically heterogeneous disorders, 2 which typically carry in common the D816V activating KIT mutation in phenotypically aberrant BMMC. 9 Despite the fact that the presence of KIT mutation has limited value for the classification of SM, it has been shown that BMMC from aggressive forms of mastocytosis (for example, ASM and MCL), systematically carry this mutation in myeloid or both myeloid and lymphoid hematopoietic cell compartments other than BMMC, 9 at the same time they display PEP associated with an increased MC immaturity.
14 Furthermore, multilineage BM involvement by the D816V KIT mutation has recently been shown to identify a subset of ISM s þ patients with increased risk of progression to more aggressive disease subtypes (for example, ASM, myelodysplastic syndrome or acute myeloblastic leukemia). 15 Despite these findings, no study has been reported so far, in which the potential association between the immunophenotype of BMMC and multilineage KIT mutation involvement has been investigated, particularly among ISM patients. This is of special relevance because current approaches to determine multilineage involvement of hematopoietic cells in SM by the KIT mutation require rather complex and time consuming technical procedures, which are not widely available for routine use (for example, flow cytometry sorting of multiple cell populations for mutational analysis). 9, 15 Here, we analyzed the PEP of BMMC from a large series of SM patients with a broad panel of proteins, in order to determine its association with the degree of involvement of different hematopoietic BM cell Figure 1 . Hierarchical clustering analysis of systemic mastocytosis (SM) bone marrow (BM) samples based on the protein expression profiles (PEP) of bone marrow mast cells (BMMC), and the BMMC load in three distinct sets of SM patients diagnosed with different subtypes of SM and distinct degree of involvement of different compartments of BM cells by the KIT D816V mutation. In panels (a) and (b) a series of 112 patients tested for a small screening panel (11 parameters) and a subset of 34 patients, in which a broader set of proteins was studied (20 parameters) are displayed, respectively. Panel (c) shows a different set of patients (validation set; n ¼ 35) analyzed for 24 different parameters, including most of the markers tested in the previous two groups of patients. Rows represent individual BM samples or patients, whereas columns represent the normalized log2 ratios of the percentage of BMMC, and the mean fluorescence intensity obtained for each marker divided by the median value obtained for that parameter in all samples tested. compartments by the KIT D816V mutation, and its potential utility as a surrogate marker for multilineage BM involvement.
Overall which typically also carry myeloid or myeloid plus lymphoid BM involvement by the KIT mutation. 9 In these ISM s þ cases, like in ASM patients, an increasing number of BM cell populations bearing the mutation was also associated with a higher BMMC load and sT levels. Likewise, BMMC from ISM s þ cases with multilineage involvement also displayed decreased expression of proteins known to be acquired during the BMMC maturation process, like FceRI, CD45 and cytoplasmic MC enzymes (for example, carboxypeptidase A and total tryptase), associated with decreased light scatter features (FSC, SSC), further confirming the immature PEP of their BMMC. 13, 14 Overall, these results suggest that in SM, the occurrence of an extended clonal hematopoiesis with multilineage involvement by KIT mutated cells could be associated with an early blockade of MC maturation, leading to more immature BMMC features and a less activated phenotype, in association with an increased MC load. As all ISM s þ cases carry in common an activating KIT mutation, 20 in principle, the mutation itself cannot fully explain such phenotypic differences; further studies are necessary to elucidate whether such maturation blockade is the result of the coexistence of additional genetic and/ or epigenetic events in the D816V þ hematopoietic precursor cell, as previously suggested for polycythemia vera, essential thrombocythemia and primary myelofibrosis cases, which share an identical activating somatic mutation of the JAK2 tyrosine kinase gene (JAK2 V617F ), but display distinct clinico-biological features. 21, 22 Alternatively, the KIT mutation could target a different stem or precursor cell in both groups of ISM s þ patients with an increased predisposition of ISM s þ cases with multilineage involvement, to acquire additional genetic events and progression to more aggressive forms of the disease. 15 This association, between the BMMC immunophenotype and the degree of BM involvement by the D816V KIT mutation, was further confirmed by the prediction algorithm developed on the basis of those variables that were identified among ISM s þ patients to discriminate between cases with MC-only vs extensive BM involvement by the KIT mutation: aberrant expression of CD25 in association with a FceRI lo , FSC lo , SSC lo and CD45 lo immature phenotype of BMMC, in the absence of coexisting BMMC with a normal phenotype. The proposed algorithm showed a high efficiency in classifying not only ISM s þ patients but also other SM patients, into cases with MC-restricted vs multilineage involvement of BM hematopoietic cells by the KIT mutation, regardless of the diagnostic subtype of the disease. Such approach can be easily implemented in routine diagnostic flow cytometry laboratories and does not require generation of a previous reference group of BM samples from SM patients, as it is based on the phenotypic features of normal or reactive BM samples. Nevertheless, it shoud be noted that differences in the sensitivity and specificity of the algorithm were observed between validation groups I and II; such differences may be due to the different number of patients included in each group (n ¼ 55 vs 20, respectively), and/or the distribution of the patients within the two groups, as the group I included only 16% (n ¼ 9/55) patients with mutlilineage KIT mutation, whereas these cases represented 60% (n ¼ 12/20) of the patients in group II; however, only few patients were misclassified in both validation sets I and II (n ¼ 4 and 3 cases, respectively). Furthermore, detection of mutilineage KIT D816V mutation using the proposed surrogate PEP algorithm had a significant impact on PFS of ISM s þ patients, identical to that provided by the investigation of the presence of the KIT mutation on purified cell populations; this is because none of the discrepant cases progressed at the moment of closing this study. Altogether, these findings support the utility of immunophenotyping of BMMC as a surrogate marker to predict the degree of clonal hematopoiesis in the BM of SM patients, independently of the clinical subtype of the disease.
In summary, our results show that the immunophenotypic profile of BMMC from ISM patients is significantly associated with the degree of BM involvement by the D816V KIT mutation, as more immature BMMC features are typically found in ISM s þ cases who carry multilineage clonal hematopoiesis; these findings suggest that the immunophenotype of BMMC may be used as a surrogate marker for the diagnostic screening of multilineage KIT mutation among ISM s þ , and therefore, prognostic stratification of this group of ISM patients.
